<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hepatitis viral &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/hepatitis-viral/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Tue, 02 Jun 2026 12:26:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Hepatitis viral &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease</title>
		<link>https://clinicaltrials.eu/trial/comparing-liquid-versus-capsule-forms-of-phosphatidylcholine-in-patients-with-alcoholic-liver-disease-chronic-hepatitis-b-and-metabolic-liver-disease/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:07:30 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/comparing-liquid-versus-capsule-forms-of-phosphatidylcholine-in-patients-with-alcoholic-liver-disease-chronic-hepatitis-b-and-metabolic-liver-disease/</guid>

					<description><![CDATA[This clinical trial studies the effectiveness of two forms of Essentiale medication (liquid and capsules) in treating several liver conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcoholic Liver Disease, and Chronic Viral Hepatitis B. The main active substance in both forms is phosphatidylcholine, which is derived from soya beans. The purpose of the study is [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial studies the effectiveness of two forms of <b>Essentiale</b> medication (liquid and capsules) in treating several liver conditions: <b>Metabolic Dysfunction-Associated Steatotic Liver Disease</b> (MASLD), <b>Alcoholic Liver Disease</b>, and <b>Chronic Viral Hepatitis B</b>. The main active substance in both forms is <b>phosphatidylcholine</b>, which is derived from soya beans. The purpose of the study is to determine if the liquid form of the medication works as well as the capsule form when added to standard treatment.</p>
<p>During the study, participants will receive either the liquid form of Essentiale (1800 mg), Essentiale capsules, or a placebo. The medication or placebo will be taken daily for 87 days. The liquid medication comes in stick packs containing 1.8g of the substance, while the capsules contain 300 mg each. All participants will continue their regular liver disease treatment throughout the study.</p>
<p>The study will monitor changes in liver disease symptoms such as tiredness, depression, stomach discomfort, sleep problems, loss of appetite, and nausea. The medications and placebos are designed to look, taste, and smell the same so that participants cannot tell which form they are receiving. This helps ensure that the study results are reliable and unbiased.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
